Alcohol
Volume 34, Issue 1 , Pages 81-87 , August 2004

Obesity and alcoholic liver disease

  • Anna Mae Diehl

      Affiliations

    • Corresponding Author InformationCorresponding author and present address: Duke University Medical Center, Genome Science Research Building-1, Suite 1073, Box 3256, 595 LaSalle Street, Durham, NC 22710, USA. Tel.: +1-919-684-4173/4160; fax: +1-919-684-8143.

Received 30 March 2004 ,Revised 7 July 2004 ,Accepted 8 July 2004.

References 

  1. Addolorato G, Capristo E, Caputo F, Greco AV, Ceccanti M, Stefanini GF, et al. Nutritional status and body fluid distribution in chronic alcoholics compared with controls. Alcohol Clin Exp Res. 1999;23:1232–1237
  2. Ahima RS, Saper CB, Flier JS, Elmquist JK. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol. 2000;21:263–307
  3. An J, Muoio DM, Shiota M, Fujimoto Y, Cline GW, Shulman GI, et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med. 2004;10:268–274
  4. Bacha F, Saad R, Gungor N, Arslanian SA. Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and β-cell function. Diab Care. 2004;27:547–552
  5. Bataller R, Ginès P, Nicolás JM, Görbig MN, Garcia-Ramallo E, Gasull X, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000;118:1149–1156
  6. Bataller R, Sancho-bru P, Ginés P, Lora JM, Al-garawi A, Solé M, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003;125:117–125
  7. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112–117
  8. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13:84–89
  9. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:519–525
  10. Campfield LA, Smith FJ, Burn P. The OB protein (leptin) pathway—a link between adipose tissue mass and central neural networks. Horm Metab Res. 1996;28:619–632
  11. Cavadas C, Grand D, Mosimann F, Cotrim MD, Fontes Ribeiro CA, Brunner HR, et al. Angiotensin II mediates catecholamine and neuropeptide Y secretion in human adrenal chromaffin cells through the AT1 receptor. Regul Pept. 2003;111:61–65
  12. Cinti S. Adipocyte differentiation and transdifferentiation: plasticity of the adipose organ. J Endocrinol Invest. 2002;25:823–835
  13. Cohen P, Zhao C, Cai X, Montez JM, Rohani SC, Feinstein P, et al. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest. 2001;108:1113–1121
  14. Commins SP, Marsh DJ, Thomas SA, Watson PM, Padgett MA, Palmiter R, et al. Norepinephrine is required for leptin effects on gene expression in brown and white adipose tissue. Endocrinology. 1999;140:4772–4778
  15. Dallongeville J, Marecaux N, Ducimetiere P, Ferrieres J, Arveiler D, Bingham A, et al. Influence of alcohol consumption and various beverages on waist girth and waist-to-hip ratio in a sample of French men and women. Int J Obes Relat Metab Disord. 1998;22:1178–1183
  16. De Silva A, De Courten M, Zimmet P, Nicholson G, Kotowicz M, Pasco J, et al. Lifestyle factors fail to explain the variation in plasma leptin concentrations in women. Nutrition. 1998;14:653–657
  17. Di Marco A, Demartis A, Gloaguen I, Lazzaro D, Delmastro P, Ciliberto G, et al. Leptin receptor-mediated regulation of cholinergic neurotransmitter phenotype in cells of central nervous system origin. Eur J Biochem. 2000;267:2939–2944
  18. Dubuisson L, Desmoulière A, Decourt B, Evadé L, Bedin C, Boussarie L, et al. Inhibition of rat liver fibrogenesis through noradrenergic antagonism. Hepatology. 2002;35:325–331
  19. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52:595–638
  20. Enomoto N, Takei Y, Hirose M, Konno A, Shibuya T, Matsuyama S, et al. Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-γ, pioglitazone. J Pharmacol Exp Ther. 2003;306:846–854
  21. Farivar RS, Crawford DC, Chobanian AV, Brecher P. Effect of angiotensin II blockade on the fibroproliferative response to phenylephrine in the rat heart. Hypertension. 1995;25:809–813
  22. Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor α (PPARα) agonist treatment reverses PPARα dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem. 2003;278:27997–28004
  23. Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?. Diabetes. 2002;51:2951–2958
  24. Ganong WF. Origin of the angiotensin II secreted by cells. Proc Soc Exp Biol Med. 1994;205:213–219
  25. Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev. 2003;4:43–55
  26. Green RM. NASH—Hepatic metabolism and not simply the metabolic syndrome. Hepatology. 2003;38:14–17
  27. Gum RJ, Gaede LL, Heindel MA, Waring JF, Trevillyan JM, Zinker BA, et al. Antisense protein tyrosine phosphatase 1B reverses activation of p38 mitogen-activated protein kinase in liver of ob/ob mice. Mol Endocrinol. 2003;17:1131–1143
  28. Hassan S, Duong B, Kim K-S, Miles MF. Pharmacogenomic analysis of mechanisms mediating ethanol regulation of dopamine β-hydroxylase. J Biol Chem. 2003;278:38860–38869
  29. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420:333–336
  30. Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology. 2001;34:288–297
  31. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang Y-J, et al. Leptin receptor–mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology. 2002;122:1399–1410
  32. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-α expression. Diabetes. 2003;52:1779–1785
  33. Kiefer F, Jahn H, Schick M, Wiedemann K. Alcohol intake, tumour necrosis factor-α, leptin and craving: factors of a possibly vicious circle?. Alcohol Alcohol. 2002;37:401–404
  34. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A. 2001;98:7522–7527
  35. Kim JK, Kim Y-J, Fillmore JJ, Chen Y, Moore I, Lee J, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest. 2001;108:437–446
  36. Klaus S. Adipose tissue as a regulator of energy balance. Curr Drug Targets. 2004;5:241–250
  37. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol. 2002;37:206–213
  38. Lelbach WK. Epidemiology of alcoholic liver disease. Prog Liver Dis. 1976;5:494–515
  39. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37:343–350
  40. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000;6:998–1003
  41. Lin HZ, Yang SQ, Zeldin G, Diehl AM. Chronic ethanol consumption induces the production of tumor necrosis factor-alpha and related cytokines in liver and adipose tissue. Alcohol Clin Exp Res. 1998;22(5 Suppl):231S–237S
  42. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144:2195–2200
  43. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893–894
  44. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923
  45. McCullough AJ, Bugianesi E, Marchesini G, Kalhan SC. Gender-dependent alterations in serum leptin in alcoholic cirrhosis. Gastroenterology. 1998;115:947–953
  46. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Medicine. 2003;82:129–146
  47. Mittelman SD, Van Citters GW, Kirkman EL, Bergman RN. Extreme insulin resistance of the central adipose depot in vivo. Diabetes. 2002;51:755–761
  48. Mora S, Pessin JE. An adipocentric view of signaling and intracellular trafficking. Diabetes Metab Res Rev. 2002;18:345–356
  49. Morgan MY. The prognosis and outcome of alcoholic liver disease. Alcohol Alcohol Suppl. 1994;2:335–343
  50. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput J-C. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25:108–111
  51. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol. 2003;38:434–440
  52. Nyholm B, Nielsen MF, Kristensen K, Nielsen S, Østergård T, Pedersen SB, et al. Evidence of increased visceral obesity and reduced physical fitness in healthy insulin resistant first-degree relatives of type 2 diabetic patients. Eur J Endocrinol. 2004;150:207–214
  53. Oben JA, Roskams T, Yang S, Lin H, Sinelli N, Li Z, et al. Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice. Biochem Biophys Res Commun. 2003;308:284–292
  54. Oben JA, Yang S, Lin H, Ono M, Diehl AM. Norepinephrine and neuropeptide Y promote proliferation and collagen gene expression of hepatic myofibroblastic stellate cells. Biochem Biophys Res Commun. 2003;302:685–690
  55. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. Structure–function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem. 2003;278:9073–9085
  56. Park HS, Sim SJ, Park JY. Effect of weight reduction on metabolic syndrome in Korean obese patients. J Korean Med Sci. 2004;19:202–208
  57. Peeraully, M. R., Jenkins, J. R., & Trayhurn, P. (Epub 20 April 2004). NGF gene expression and secretion in white adipose tissue: regulation in 3T3-L1 adipocytes by hormones and inflammatory cytokines. American Journal of Physiology - Endocrinology and Metabolism; doi:10.1152/ajpendo.00076.2004 0193-1849/04. (For reader information: subsequent print publication, Am J Physiol Endocrinol Metab 287, E331–E339.)
  58. Pequignot G, Tuyns AJ, Berta JL. Ascitic cirrhosis in relation to alcohol consumption. Int J Epidemiol. 1978;7:113–120
  59. Potter JJ, Mezey E. Leptin deficiency reduces but does not eliminate the development of hepatic fibrosis in mice infected with Schistosoma mansoni. Liver. 2002;22:173–177
  60. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput J-C, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 2002;35:635–638
  61. Rayner DV, Simón E, Duncan JS, Trayhurn P. Hyperleptinaemia in mice induced by administration of the tyrosine hydroxylase inhibitor α-methyl-p-tyrosine. FEBS Lett. 1998;429:395–398
  62. Röjdmark S, Calissendorff J, Brismar K. Alcohol ingestion decreases both diurnal and nocturnal secretion of leptin in healthy individuals. Clin Endocrinol (Oxf). 2001;55:639–647
  63. Santolaria F, Pérez-Cejas A, Alemán M-R, González-Reimers E, Milena A, De La Vega M-J, et al. Low serum leptin levels and malnutrition in chronic alcohol misusers hospitalized by somatic complications. Alcohol Alcohol. 2003;38:60–66
  64. Sasaki Y, Wands JR. Ethanol impairs insulin receptor substrate-1 mediated signal transduction during rat liver regeneration. Biochem Biophys Res Commun. 1994;199:403–409
  65. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology. 2002;35:762–771
  66. Shirai K. Obesity as the core of the metabolic syndrome and management of coronary heart disease. Curr Med Res Opin. 2004;20:295–304
  67. Sizemore N, Lerner N, Dombrowski N, Sakurai H, Stark GR. Distinct roles of the IκB kinase α and β subunits in liberating nuclear factor κB (NF-κB) from IκB and in phosphorylating the p65 subunit of NF-κB. J Biol Chem. 2002;277:3863–3869
  68. Sussman S, Dent CW, Skara S, de Calice P, Tsukamoto H. Alcoholic liver disease (ALD): a new domain for prevention efforts. Subst Use Misuse. 2002;37:1887–1904
  69. Szabo G. Pathogenic interactions between alcohol and hepatitis C. Curr Gastroenterol Rep. 2003;5:86–92
  70. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111:305–317
  71. Takekoshi K, Motooka M, Isobe K, Nomura F, Manmoku T, Ishii K, et al. Leptin directly stimulates catecholamine secretion and synthesis in cultured porcine adrenal medullary chromaffin cells. Biochem Biophys Res Commun. 1999;261:426–431
  72. Tallaj J, Wei C-C, Hankes GH, Holland M, Rynders P, Dillon AR, et al. β1-adrenergic receptor blockade attenuates angiotensin II–mediated catecholamine release into the cardiac interstitium in mitral regurgitation. Circulation. 2003;108:225–230
  73. Thiele TE, Marsh DJ, Ste. Marie L, Bernstein IL, Palmiter RD. Ethanol consumption and resistance are inversely related to neuropeptide Y levels. Nature. 1998;396:366–369
  74. Tobe K, Suzuki R, Aoyama M, Yamauchi T, Kamon J, Kubota N, et al. Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2−/− mouse liver. J Biol Chem. 2001;276:38337–38340
  75. Togo M, Hashimoto Y, Futamura A, Tsukamoto K, Satoh H, Hara M, et al. Relationship between the serum level of leptin and life-style habits in Japanese men. Horm Res. 2000;54:169–173
  76. Tsukamoto H, Lu SC. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J. 2001;15:1335–1349
  77. Turtzo LC, Marx R, Lane MD. Cross-talk between sympathetic neurons and adipocytes in coculture. Proc Natl Acad Sci U S A. 2001;98:12385–12390
  78. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45–65
  79. Wajchenberg BL, Giannella-Neto D, da Silva MER, Santos RF. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res. 2002;34:616–621
  80. Wakabayashi I, Kobaba-Wakabayashi R, Masuda H. Relation of drinking alcohol to atherosclerotic risk in type 2 diabetes. Diabetes Care. 2002;25:1223–1228
  81. Weinshenker D, Rust NC, Miller NS, Palmiter RD. Ethanol-associated behaviors of mice lacking norepinephrine. J Neurosci. 2000;20:3157–3164
  82. Xu A, Wang Y, Keshaw H, Xu LY, Lam KSL, Cooper GJS. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91–100
  83. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762–769
  84. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34:745–750
  85. You M, Fischer M, Deeg MA, Crabb DW. Ethanol induces fatty acid synthesis pathways by activation of sterol regulatory element-binding protein (SREBP). J Biol Chem. 2002;277:29342–29347
  86. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li Z-W, Karin M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKβ. Science. 2001;293:1673–1677
  87. Zeng C, Zhou Y, Liu G, Sun W. The signal transduction pathway causing the synergistic hypertrophic effects of neuropeptide Y and norepinephrine on primary cardiomyocyte. Neuropeptides. 2001;35:211–218

PII: S0741-8329(04)00161-2

doi: 10.1016/j.alcohol.2004.07.010

Alcohol
Volume 34, Issue 1 , Pages 81-87 , August 2004

Article Tools